UNSPSC 51421904: Cortisone acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C23H30O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 883WKN7W8X, chemically known as 4-pregnene-3,11,20-trione, 17alpha,21-dihydroxy-, 21-acetate but more generally known as cortisone acetate, which bears US NIH Compound Identifier 2863. European Medicines Agency schedules Cortisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01467MIG.

Most nations, for tariff and trade purposes, schedule cortisone acetate under HS 29372100 and SITC 54153. As of Q4 2014, CORTISONE ACETATE remains US FDA's Preferred Term for this commodity. Cortisone acetate bears US NLM identifiers UMLS ID C0056391 and NCI Concept Code C1058. SMILES: CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O.

UNSPSC 51421904 Cortisone acetate (Commodity) shows minimal recent state and local procurement activity aligned with its nominal scope. The two opportunities posted under this code in the recent window—a Seminole County, Florida IFB for naloxone and drug deactivation systems and a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs—are plainly unrelated to cortisone acetate procurement. Neither solicitation names cortisone acetate or corticosteroid pharmaceutical products as a line item or procurement focus. The mismatch suggests that the code may be mistagged on these opportunities or that state and local buyers are not currently using it for its intended pharmaceutical commodity classification.

Without recent solicitations actually seeking cortisone acetate, no reliable signal emerges about issuing-body mix, geographic concentration, or current market demand under this code. State and local procurement activity at the Commodity tier for pharmaceutical products varies significantly by agency mission and formulary requirements—state health departments, correctional systems, and Medicaid programs are typical buyers—but no recent opportunities support characterization of who is buying, where, or under what terms. Firms pursuing pharmaceutical supply contracts at the state and local level should monitor this code for activity but should not rely on the current record as evidence of sustained demand or procurement patterns.